EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Can melatonin reduce the severity of post-COVID-19 syndrome?

Amine Souissi, Ismail Dergaa, Mohamed Romdhani, Amine Ghram, Khadijeh Irandoust, Karim Chamari, Helmi Ben Saad

EXCLI Journal · 02.02.2023 · 22 · 173-187

DOI: 10.17179/excli2023-5864 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 02.02.2023. Verfasst von Amine Souissi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Université de Sousse, Faculté de Médecine de Sousse, Hôpital Farhat HACHED, Laboratoire de Recherche (Insuffisance Cardiaque, LR12SP09), Sousse, Tuni…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This short review aimed at (i) providing an update on the health benefits associated with melatonin supplementation, while (ii) considering future potential research directions concerning melatonin supplementation use relative to Coronavirus disease of 2019 (COVID-19). A narrative review of the literature was undertaken to ascertain the effect of exogenous melatonin administration on humans. Night-time melatonin administration has a positive impact on human physiology and mental health. Indeed, melatonin (i) modulates the circadian components of the sleep-wake cycle; (ii) improves sleep efficiency and mood status; (iii) improves insulin sensitivity; and (iv) reduces inflammatory markers and oxidative stress. Melatonin has also remarkable neuroprotective and cardioprotective effects and may therefore prevent deterioration caused by COVID-19. We suggest that melatonin could be used as a potential therapy in the post-COVID-19 syndrome, and therefore call for action the research community to investigate on the potential use of exogenous melatonin to enhance the quality of life in patients with post-COVID-19 syndrome.

Schlagwörter

Stichwörter der Autor:innen

antioxidant statuscytokinesdosefree radicalsstress

Autor:innen und Institutionen

  • Université de Sousse, Faculté de Médecine de Sousse, Hôpital Farhat HACHED, Laboratoire de Recherche (Insuffisance Cardiaque, LR12SP09), Sousse, Tunisie.
  • Primary Health Care Corporation (PHCC), Doha, P.O. Box 26555, Qatar.
  • Research Unit: Physical Activity, Sport, and Health, UR18JS01, National Observatory of Sport, Tunis, Tunisia.
  • Motricité-Interactions-Performance, MIP, UR4334, Le Mans Université, Le Mans, France.
  • Department of Sport Sciences, Imam Khomeini International University, Qazvin, Iran.
  • Aspetar, Orthopedic and Sports Medicine Hospital, FIFA Medical Center of Excellence, Doha, Qatar.

Zitieren

APA

Souissi, A., Dergaa, I., Romdhani, M., Ghram, A., Irandoust, K., Chamari, K., & Ben Saad, H. (2023). Can melatonin reduce the severity of post-COVID-19 syndrome?. EXCLI Journal, 22, 173-187. https://doi.org/10.17179/excli2023-5864

Vancouver

Souissi A, Dergaa I, Romdhani M, Ghram A, Irandoust K, Chamari K, et al. Can melatonin reduce the severity of post-COVID-19 syndrome?. EXCLI Journal. 2023;22:173-187. doi:10.17179/excli2023-5864

BibTeX
@article{Souissi2023,
  author = {Souissi, Amine and Dergaa, Ismail and Romdhani, Mohamed and Ghram, Amine and Irandoust, Khadijeh and Chamari, Karim and Ben Saad, Helmi},
  title = {Can melatonin reduce the severity of post-COVID-19 syndrome?},
  journal = {EXCLI Journal},
  year = {2023},
  volume = {22},
  pages = {173--187},
  doi = {10.17179/excli2023-5864}
}
Kostenlos starten →